Novartis Prostate Cancer Drug Receives Breakthrough Designation by US FDA
On Wednesday, 16th June 2021, the Swiss drug making company Novartis AG has received the breakthrough therapy designation from the Food and Drug Administration (FDA) of the United States of America for the purpose of an experimental treatment for the advanced castration-resistant prostate cancer. The men suffering from the prostate cancer, which has been spread […]
Continue Reading